Global View Capital Management LLC Acquires Shares of 543 Eli Lilly and Company (NYSE:LLY)

Global View Capital Management LLC acquired a new stake in Eli Lilly and Company (NYSE:LLY) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 543 shares of the company’s stock, valued at approximately $422,000.

A number of other institutional investors have also recently bought and sold shares of the business. Principal Financial Group Inc. lifted its holdings in shares of Eli Lilly and Company by 5.3% during the 3rd quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock worth $1,070,698,000 after acquiring an additional 60,306 shares during the period. XML Financial LLC lifted its holdings in shares of Eli Lilly and Company by 1.0% during the 3rd quarter. XML Financial LLC now owns 1,775 shares of the company’s stock worth $1,572,000 after acquiring an additional 17 shares during the period. Arvest Investments Inc. lifted its holdings in shares of Eli Lilly and Company by 5.1% during the 3rd quarter. Arvest Investments Inc. now owns 870 shares of the company’s stock worth $771,000 after acquiring an additional 42 shares during the period. Los Angeles Capital Management LLC lifted its holdings in shares of Eli Lilly and Company by 0.9% during the 3rd quarter. Los Angeles Capital Management LLC now owns 468,385 shares of the company’s stock worth $414,961,000 after acquiring an additional 4,390 shares during the period. Finally, Ashton Thomas Securities LLC lifted its holdings in shares of Eli Lilly and Company by 41.2% during the 3rd quarter. Ashton Thomas Securities LLC now owns 3,782 shares of the company’s stock worth $3,351,000 after acquiring an additional 1,103 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 4.7 %

Shares of NYSE LLY opened at $828.80 on Tuesday. Eli Lilly and Company has a 52-week low of $711.40 and a 52-week high of $972.53. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The firm has a 50 day moving average price of $827.73 and a two-hundred day moving average price of $846.36. The stock has a market cap of $785.84 billion, a P/E ratio of 70.78, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company announced that its board has authorized a stock buyback program on Monday, December 9th that permits the company to buyback $15.00 billion in shares. This buyback authorization permits the company to repurchase up to 2% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Berenberg Bank set a $970.00 price target on shares of Eli Lilly and Company in a report on Thursday, January 16th. Citigroup lowered their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Truist Financial upped their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. Morgan Stanley set a $1,146.00 price objective on shares of Eli Lilly and Company in a research report on Thursday. Finally, Leerink Partners set a $950.00 price objective on shares of Eli Lilly and Company in a research report on Friday, January 17th. Three investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,009.72.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.